CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

被引：201

作者：

Buerger, K

Teipel, SJ

Zinkowski, R

Blennow, K

Arai, H

Engel, R

Hofmann-Kiefer, K

McCulloch, C

Ptok, U

Heun, R

Andreasen, N

DeBernardis, J

Kerkman, D

Moeller, HJ

Davies, P

Hampel, H

机构：

[1] Mol Geriatr Corp, Vernon Hills, IL 60061 USA

[2] Univ Munich, Dementia Res Sect, Munich, Germany

[3] Univ Munich, Memory Clin, Munich, Germany

[4] Univ Munich, Alzheimer Mem Ctr, Dept Psychiat, Munich, Germany

[5] Univ Munich, Dept Anesthesiol, Munich, Germany

[6] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Neurosci, Unit Neurochem, Molndal, Sweden

[7] Tohoku Univ, Sch Med, Dept Geriatr Med, Sendai, Miyagi 980, Japan

[8] Univ Bonn, Dept Psychiat, D-5300 Bonn, Germany

[9] Pitea River Valley Hosp, Dept Rehabil, Pitea, Sweden

[10] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA

来源：

NEUROLOGY | 2002年 / 59卷 / 04期

关键词：

D O I：

10.1212/WNL.59.4.627

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In this longitudinal study of 77 patients with mild cognitive impairment (MCI), the authors analyzed whether levels of tau protein phosphorylated at threonine 231 (p-tau(231)) in CSF correlate with progression of cognitive decline. High CSF p-tau(231) levels at baseline, but not total tau protein levels, correlated with cognitive decline and conversion from MCI to AD. Independently, old age and APOE-epsilon4 carrier status were predictive as well. Our data indicate that an increased p-tau(231) level is a potential risk factor for cognitive decline in patients with MCI.

引用

页码：627 / 629

页数：3

共 10 条

[1] Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109
[2] Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
Andreasen, N
Minthon, L
Vanmechelen, E
Vanderstichele, H
Davidsson, P
Winblad, B
Blennow, K
[J]. NEUROSCIENCE LETTERS, 1999, 273 (01) : 5 - 8
[3] CSF phosphorylated tau protein and mild cognitive impairment: a prospective study
Arai, H
Ishiguro, K
Ohno, H
Moriyama, M
Itoh, N
Okamura, N
Matsui, T
Morikawa, Y
Horikawa, E
Kohno, H
Sasaki, H
Imahori, K
[J]. EXPERIMENTAL NEUROLOGY, 2000, 166 (01) : 201 - 203
[4] CSF total tau, aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease
Blennow, K
Vanmechelen, E
Hampel, H
[J]. MOLECULAR NEUROBIOLOGY, 2001, 24 (1-3) : 87 - 97
[5] Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease
Convit, A
de Asis, J
de Leon, MJ
Tarshish, CY
De Santi, S
Rusinek, H
[J]. NEUROBIOLOGY OF AGING, 2000, 21 (01) : 19 - 26
[6] Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231
Hampel, H
Buerger, K
Kohnken, R
Teipel, SJ
Zinkowski, R
Moeller, HJ
Rapoport, SI
Davies, P
[J]. ANNALS OF NEUROLOGY, 2001, 49 (04) : 545 - 546
[7] THE PREVALENCE OF DEMENTIA - A QUANTITATIVE INTEGRATION OF THE LITERATURE
JORM, AF
KORTEN, AE
HENDERSON, AS
[J]. ACTA PSYCHIATRICA SCANDINAVICA, 1987, 76 (05) : 465 - 479
[8] Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients
Kohnken, R
Buerger, K
Zinkowski, R
Miller, C
Kerkman, D
DeBernardis, J
Shen, JF
Möller, HJ
Davies, P
Hampel, H
[J]. NEUROSCIENCE LETTERS, 2000, 287 (03) : 187 - 190
[9] APOLIPOPROTEIN-E STATUS AS A PREDICTOR OF THE DEVELOPMENT OF ALZHEIMERS-DISEASE IN MEMORY-IMPAIRED INDIVIDUALS
PETERSEN, RC
SMITH, GE
IVNIK, RJ
TANGALOS, EG
SCHAID, DJ
THIBODEAU, SN
KOKMEN, E
WARING, SC
KURLAND, LT
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (16): : 1274 - 1278
[10] Mitotic phosphoepitopes precede paired helical filaments in Alzheimer's disease
Vincent, I
Zheng, JH
Dickson, DW
Kress, Y
Davies, P
[J]. NEUROBIOLOGY OF AGING, 1998, 19 (04) : 287 - 296

← 1 →